FDA Complete Response Letter for Investigational Cabotegravir and Rilpivirine Long-Acting HIV Treatment

TITUSVILLE, N.J., December 21, 2019– The Janssen Pharmaceutical Companies of Johnson& Johnson announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) in response to ViiV Healthcare’s...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials